Circulating CD36 and oxLDL levels are associated with cardiovascular risk factors in young subjects

BMC Cardiovascular Disorders

Isela Parra-Rojas¹  Natividad Castro-Alarcón¹  Aralia B Salgado-Bernabé¹  Ulises De la Cruz-Mosso²  José F Muñoz-Valle²  Luz E Ramos-Arellano¹ 

[1] Laboratorio de Investigación en Obesidad y Diabetes, Unidad Académica de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, México;Departamento de Biología Molecular y Genómica, Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México

关键词: Obesity;    Cardiovascular risk factors;    OxLDL;    CD36;   

Others  :  855127
DOI  :  10.1186/1471-2261-14-54

 received in 2013-12-08, accepted in 2014-04-23,  发布年份 2014

【 摘 要 】

Background

Cardiovascular disease (CVD) results from a combination of abnormalities in lipoprotein metabolism, oxidative stress, chronic inflammation, and susceptibility to thrombosis. Atherosclerosis is the major cause of CVD. CD36 has been shown to play a critical role in the development of atherosclerotic lesions by its capacity to bind and promote endocytosis of oxidized low-density lipoprotein (oxLDL) and is implicated in the formation of foam cells. The purpose of this research was to evaluate whether there is an association of sCD36 and oxLDL levels with cardiovascular risk factors in young subjects.

Methods

A total of 188 subjects, 18 to 25 years old, 133 normal-weight and 55 obese subjects from the state of Guerrero, Mexico were recruited in the study. The lipid profile and glucose levels were measured by enzymatic colorimetric assays. Enzyme-linked immunosorbant assays (ELISA) for oxLDL and sCD36 were performed. Statistical analyses of data were performed with Wilcoxon- Mann Whitney and chi-square tests as well as with multinomial regression.

Results

TC, LDL-C, TG, oxLDL and sCD36 levels were higher in obese subjects than in normal-weight controls, as well as, monocyte and platelet counts (P < 0.05). Obese subjects had 5.8 times higher risk of sCD36 in the third tertil (>97.8 ng/mL) than normal-weight controls (P = 0.014), and 7.4 times higher risk of oxLDL levels in third tertile (>48 U/L) than control group. The subjects with hypercholesterolemia, hypertriglyceridemia, fasting impaired LDL-C had a higher risk of oxLDL levels in the third tertile (>48 U/L) than the control group (P < 0.05).

Conclusions

Circulating CD36 and oxLDL levels are associated with cardiovascular risk factors in young subjects and may be potential early markers for cardiovascular disease (CVD).

【 授权许可】

   
2014 Ramos-Arellano et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Lin CM, Li CY: Prevalence of Cardiovascular Risk Factors in Taiwanese Healthcare Workers. Ind Health 2009, 47(4):411-418.
• [2]Ros E: Nuts and novel biomarkers of cardiovascular disease. Am J Clin Nutr 2009, 89(5):1649S-1656S.
• [3]Scott J: Pathophysiology and biochemistry of cardiovascular disease. Curr Opin Genet Dev 2004, 14(3):271-279.
• [4]Douglas G, Channon KM: The pathogenesis of atherosclerosis. Medicine 2010, 38(8):397-402.
• [5]Glaudemans AW, Slart RH, Bozzao A, Bonanno E, Arca M, Dierckx RA, Signore A: Molecular imaging in atherosclerosis. Eur J Nucl Med Mol Imaging 2010, 37(12):2381-2397.
• [6]Lakshmy R, Ahmad D, Abraham RA, Sharma M, Vemparala K, Das S, Reddy KS, Prabhakaran D: Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocardial infarction & association with oxidized low density lipoprotein. Indian J Med Res 2010, 131:522-529.
• [7]Rosoky RM, Wolosker N, Nasser M, Zerati AE, Gidlund M, Puech-Leão P: Oxidized low-density lipoprotein and ankle-brachial pressure index in patients with clinically evident peripheral arterial disease. Clinics 2010, 65(4):383-387.
• [8]Silverstein RL: Inflammation, atherosclerosis, and arterial thrombosis: role of the scavenger receptor CD36. Cleve Clin J Med 2009, 76(2):S27-S30.
• [9]Rasouli N, Yao-Borengasser A, Varma V, Spencer HJ, McGehee RE Jr, Peterson CA, Mehta JL, Kern PA: Association of scavenger receptors in adipose tissue with insulin resistance in nondiabetic humans. Arterioscler Thromb Vasc Biol 2009, 29(9):1328-1335.
• [10]Crucet M, Wüst SJ, Spielmann P, Lüscher TF, Wenger RH, Matter CM: Hypoxia enhances lipid uptake in macrophages: Role of the scavenger receptors Lox1, SRA, and CD36. Atherosclerosis 2013, 229(1):110-117.
• [11]Cho S, Kim E: CD36: a multi-modal target for acute stroke therapy. J Neurochem 2009, 109(1):126-132.
• [12]Cho S: CD36 as a therapeutic target for endothelial dysfunction in stroke. Curr Pharm Des 2012, 18(25):3721-3730.
• [13]Febbraio M, Silverstein RL: CD36: Implications in Cardiovascular Disease. Int J Biochem Cell Biol 2007, 39(11):2012-2030.
• [14]Erdman LK, Cosio G, Helmers AJ, Gowda DC, Grinstein S, Kain KC: CD36 and TLR interactions in inflammation and phagocytosis: implications for malaria. J Immunol 2009, 183(10):6452-6459.
• [15]Glintborg D, Højlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A: Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 2008, 31(2):328-334.
• [16]Ghosh A, Li W, Febbraio M, Espinola RG, McCrae KR, Cockrell E, Silverstein RL: Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest 2008, 118(5):1934-1943.
• [17]Petta S, Handberg A, Marchesini G, Cammà C, Di Marco V, Cabibi D, Macaluso FS, Craxì A: High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. J Viral Hepat 2013, 20(3):174-182.
• [18]Collot-Teixeira S, Martin J, McDermott-Roe C, Poston R, McGregor JL: CD36 and macrophages in atherosclerosis. Cardiovasc Res 2007, 1(75):468-477.
• [19]Montano EN, Boullier A, Almazan F, Binder CJ, Witztum JL, Hartvigsen K: Development and Application of a Non-Radioactive Binding Assay of Oxidized LDL to Macrophage Scavenger Receptors. J Lipid Res 2013, 54(11):3206-3214.
• [20]Yu XH, Fu YC, Zhang DW, Yin K, Tang CK: Foam cells in atherosclerosis. Clin Chim Acta 2013, 424:245-252.
• [21]Handberg A, Levin K, Højlund K, Beck-Nielsen H: Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma. novel marker of insulin resistance. A Circulation 2006, 114:1169-1176.
• [22]Fernández-Real JM, Handberg A, Ortega F, Højlund K, Vendrell J, Ricart W: Circulating soluble CD36 is a novel marker of liver injury in subjects with altered glucose tolerance. J Nutr Biochem 2009, 20(6):477-484.
• [23]Handberg A, Højlund K, Gastaldelli A, Flyvbjerg A, Dekker JM, Petrie J, Piatti P, Beck-Nielsen H: Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Intern Med 2012, 271:294-304.
• [24]Koonen DP, Jensen MK, Handberg A: Soluble CD36- a marker of the (pathophysiological) role of CD36 in the metabolic syndrome? Arch Physiol Biochem 2011, 117(2):57-63.
• [25]Alkhatatbeh MJ, Mhaidat NM, Enjeti AK, Lincz LF, Thorne RF: The putative diabetic plasma marker, soluble CD36, is non-cleaved, non-soluble and entirely associated with microparticles. J Thromb Haemost 2011, 9(4):844-851.
• [26]1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension: Guidelines Subcommittee. J Hypertens 1999, 17(2):151-183.
• [27]National Cholesterol Education Program (NCEP) Expert Panel on Detection: Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002, 106(25):3143-3421.
• [28]McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ: Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr 2007, 150(6):640-644.
• [29]Francischetti EA, Genelhu VA: Obesity-hypertension: an ongoing pandemic. Int J Clin Pract 2007, 61(2):269-280.
• [30]Martin LJ, Woo JG, Daniels SR, Goodman E, Dolan LM: The Relationships of Adiponectin with Insulin and Lipids Are Strengthened with Increasing Adiposity. J Clin Endocrinol Metab 2005, 90(7):4255-4259.
• [31]Schipper HS, Nuboer R, Prop S, van den Ham HJ, de Boer FK, Kesmir C, Mombers IM, van Bekkum KA, Woudstra J, Kieft JH, Hoefer IE, de Jager W, Prakken B, van Summeren M, Kalkhoven E: Systemic inflammation in childhood obesity: circulating inflammatory mediators and activated CD14++ monocytes. Diabetologia 2012, 55(10):2800-2810.
• [32]Zaldivar F, McMurray RG, Nemet D, Galassetti P, Mills PJ, Cooper DM: Body fat and circulating leukocytes in children. Int J Obes 2006, 30(6):906-911.
• [33]Kullo IJ, Hensrud DD, Allison TG: Comparison of numbers of circulating blood monocytes in men grouped by body mass index (<25, 25 to <30, > or =30). Am J Cardiol 2002, 89(12):1441-1443.
• [34]Nieman DC, Henson DA, Nehlsen-Cannarella SL, Ekkens M, Utter AC, Butterworth DE, Fagoaga OR: Influence of obesity on immune function. J Am Diet Assoc 1999, 99(3):294-299.
• [35]Foschini D, Santos RV, Prado WL, de Piano A, Lofrano MC, Martins AC, Carnier J, Caranti DA, Sanches Pde L, Tock L, Mello MT, Tufik S, Dâmaso AR: Platelet and leptin in obese adolescents. J Pediatr (Rio J) 2008, 84(6):516-521.
• [36]Samocha-Bonet D, Justo D, Rogowski O, Saar N, Abu-Abeid S, Shenkerman G, Shapira I, Berliner S, Tomer A: Platelet counts and platelet activation markers in obese subjects. Mediators Inflamm 2008, 2008:834153. doi:10.1155/2008/834153
• [37]Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H: Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflamatory thrombocytosis. Blood 2001, 98(9):2720-2725.
• [38]Hill RJ, Warren MK, Stenberg P, Levin J, Corash L, Drummond R, Baker G, Levin F, Mok Y: Stimulation of megakaryocytopoiesis in mice by human recombinant interleukin-6. Blood 1991, 77(1):42-48.
• [39]Lyngsø D, Simonsen L, Bülow J: Interleukin-6 production in human subcutaneous abdominal adipose tissue: the effect of exercise. J Physiol 2002, 543(1):373-378.
• [40]Handberg A, Norberg M, Stenlund H, Hallmans G, Attermann J, Eriksson JW: Soluble CD36 (sCD36) Clusters with Markers of Insulin Resistance, and High sCD36 Is Associated with Increased Type 2 Diabetes Risk. J Clin Endocrinol Metab 2010, 95(4):1939-1946.
• [41]Handberg A, Lopez-Bermejo A, Bassols J, Vendrell J, Ricart W, Fernandez-Real JM: Circulating soluble CD36 is associated with glucose metabolism and interleukin-6 in glucose-intolerant men. Diabetes Vasc Dis Res 2009, 6(1):15-20.
• [42]Liani R, Halvorsen B, Sestili S, Handberg A, Santilli F, Vazzana N, Formoso G, Aukrust P: Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. Free Radic Biol Med 2012, 52(8):1318-1324.
• [43]Alkhatatbeh MJ, Enjeti AK, Acharya S, Thorne RF, Lincz LF: The origin of circulating CD36 in type 2 diabetes. Nutr Diabetes 2013, e59. doi:10.1038/nutd.2013.1
• [44]Neuparth MJ, Brandão J, Santos A, Coimbra S: Adipokines, Oxidized Low- Density Lipoprotein, and C-Reactive Protein Levels in Lean, Overweight, and Obese Portuguese Patients with Type 2 Diabetes. ISRN Obesity 2013, 142097:7. doi/10.1155/2013/142097
• [45]Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales- González A, Esquivel-Chirino C, Durante-Montiel I, Sánchez-Rivera G, Valadez-Vega C, Morales-González JA: Inflammation, Oxidative Stress, and Obesity. Int J Mol Sci 2011, 12(5):3117-3132.
• [46]Savini I, Catani MV, Evangelista D, Gasperi V, Avigliano L: Obesity-associated oxidative stress: strategies finalized to improve redox state. Int J Mol Sci 2013, 14(5):10497-10538.
• [47]Himoto T, Tani J, Miyoshi H, Morishita A, Yoneyama H, Kurokohchi K, Inukai M, Masugata H, Goda F, Senda S, Haba R, Ueno M, Yamaoka G, Masaki T: Investigation of the factors associated with circulating soluble CD36 levels in patients with HCVrelated chronic liver disease. Diabetol Metab Synd 2013, 5(1):51. BioMed Central Full Text
• [48]Kopprasch S, Pietzsch J, Kuhlisch E, Fuecker K, Temelkova-Kurktschiev T, Hanefeld M, Kühne H, Julius U, Graessler J: In Vivo Evidence for Increased Oxidation of Circulating LDL in Impaired Glucose Tolerance. Diabetes 2002, 51(10):3102-3106.
• [49]Ruíz-Hernández N, Espinoza-Zavala M, González JC, Leal-Herrera U, Reigosa-Yaniz A: Oxidized LDL and anti-oxidized LDL antibodies according uric acid levels in overweight women. Arch Cardiol Mex 2011, 81(3):188-96.
• [50]Handberg A, Højlund K, Gastaldelli A, Flyvbjerg A, Dekker JM, Petrie J, Piatti P, Beck-Nielsen H, RISC Investigators: Plasma sCD36 is associated withmarkers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Intern Med 2012, 271(3):294-304.
• [51]Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de Werf F: Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001, 21(5):844-848.
• [52]Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D: Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998, 98(15):1487-1494.
• [53]Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, Suzuki T, Nagai R: Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000, 20(10):2243-2247.
• [54]Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE: Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001, 103(15):1955-1960.
• [55]Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, Goodpaster B, Harris TB: The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004, 53(4):1068-1073.